We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Mechanism Boosts Effects of Cancer Treatments

By Biotechdaily staff writers
Posted on 06 Dec 2004
Scientists have found a new mechanism of pathway activation known to be involved in many cancers. More...
In addition, they discovered that when this mechanism is blocked, cells may become more sensitive to chemotherapeutic agents and radiation, thereby making them easier to kill.

Researchers from Mount Sinai School of Medicine (New York, NY, USA) studied the Wnt pathway, which is known to be essential to regulation of cell differentiation. Once differentiated, cell proliferation is restricted. When triggered, the Wnt pathway instructs cells not to differentiate, allowing them to grow uncontrollably, which can then lead to tumor development.

The Mount Sinai investigators found that in some ovarian, breast, and colon cancer cells this pathway becomes activated by the triggering of a receptor on the surface of the cell. The cell can stimulate itself, remain in an undifferentiated condition, and continue to grow unchecked. Also, they found that the pathway can be inactivated at the cell surface by compounds that block the receptor. When inactivated, these cancer cells become more sensitive to agents that induce cell death.

Whereas it has been known that the Wnt pathway is involved in nearly all cases of colon cancer and in some ovarian and skin cancers, this research was the first to implicate this pathway in breast cancer and to identify this mechanism in human tumor cells. The study was published in the November 2004 issue of Cancer Cell.

"An increasing number of cancer therapeutic agents are being developed to block pathways activated by interactions at the cell surface. This research provides a novel target to interfere with a pathway that is implicated in many cancer types,” remarked Dr. Stuart Aaronson, professor and chairman of oncologic sciences at Mount Sinai School of Medicine.

Dr. Anna Bafico, assistant professor of oncologic sciences at Mount Sinai concluded, "Selectively interfering in this pathway in cancer cells with this mechanism may make them more sensitive to existing treatments.”


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Spinal Fluid Cell Count Control
Spinalscopics
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.